Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Mar 14, 2023 12:41pm
365 Views
Post# 35337634

H.C. mainwright re- issues buy rating @ $15 USD for oncy

H.C. mainwright re- issues buy rating @ $15 USD for oncy

I can't access, but was contacted by someone who can.
H.C. Mainwright, today reinstated buy rating with $15 target.
that, & the silly low price IMHO is driving todays recovery.
long way to go.
before anyone comments. That number is interesting!
from one POV, quite high. The consensus average is around $$6-$7.
From a potential opportunity POV ...very low.
even the most conservative Estimate by RBC gives Onc an $18 upside, should they announce a phase 3 partnership or further results out of any study.
The HC mainwright uses standard present value discount of potential future earnings. 
they are using a 45% probability with MBc & 25% with panc @ a12% discount rate.
point being, when they get to phase 3 both MBc & panc double in probability.
the discount rate easily tripled.
moving the target well above $30.
people need to understand the trading price has little to to with ONCs real value.
The takeover value is based on potential future income.
The presentation June 2-6th, is expected to open some new eyes & windows.

 

<< Previous
Bullboard Posts
Next >>